碘难治性分化型甲状腺癌经索拉非尼治疗致亚急性肝衰竭一例

A case of subacute liver failure caused by sorafenib treatment of radioiodine-refractory differentiated thyroid cancer

笔者报道了1例碘难治性分化型甲状腺癌(RAIR-DTC)经索拉非尼治疗致亚急性肝衰竭的病例,并从临床症状、实验室检查、影像学检查、组织病理学检查结果以及患者的临床处置与转归等方面综合分析了该病的特点。笔者通过文献复习加深了对RAIR-DTC以及索拉非尼治疗晚期甲状腺癌的疗效和相关不良反应的认识,旨在提示临床医师在遇到相似病例时,不仅要关注索拉非尼的疗效,也要提高对应用靶向药物治疗RAIR-DTC所致不良反应的认知和管理,从而提高靶向治疗的疗效和安全性。

This paper reports a case of subacute liver failure caused by sorafenib treatment of radioiodine-refractory differentiated thyroid cancer(RAIR-DTC),and comprehensively analyzes the characteristics of the disease from clinical symptoms,laboratory examinations,imaging examinations,histopathological examination results as well as the patient's clinical treatment and outcome.Through literature review,the authors deepen the understanding of the characteristics of the disease,the efficacy and adverse reactions of sorafenib in the treatment of advanced thyroid cancer.This paper aims to remind clinicians that when encountering similar cases,they should not only pay attention to the efficacy of sorafenib treatment,but also improve the clinical awareness and management of adverse reactions related to the application of targeted drug therapy in RAIR-DTC,and ultimately improve the efficacy and safety of targeted therapy.